Agenus Inc - Company Profile

Powered by

All the data and insights you need on Agenus Inc in one report.

$ $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date Agenus Inc Strategy Report

  • Understand Agenus Inc position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Agenus Inc: Overview

Select Item

Agenus Inc (Agenus), formerly, Antigenics Inc, is a clinical-stage immuno-oncology company that discovers, develops and commercializes immunotherapeutics for the treatment of various types of cancers and infectious diseases. The company’s pipeline portfolio encompasses vaccines for glioblastoma, genital herpes, and multiple cancer types; vaccine adjuvants for the treatment of shingles and malaria; and checkpoint antibodies targeted at various diseases. The company's technology portfolio includes antibody discovery platform, vaccine platforms and Heat Shock Protein (HSP) platform. It operates in the US and Europe. Agenus is headquartered in Lexington, Massachusetts, the US.

 Gain a 360-degree view of Agenus Inc and make more informed decisions for your business Gain a 360-degree view of Agenus Inc and make more informed decisions for your business Find out more
Headquarters United States of America
Address 3 Forbes Rd, Lexington, Massachusetts, 02421-7305
Website agenusbio.com
Telephone 1 781 6744400
No of Employees 389
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange AGEN (NASD)
Revenue (2022) $156.3M 59.5% (2022 vs 2021)
EPS XYZ
Net Income (2022) XYZ -11.7% (2022 vs 2021)
Market Cap* $113.1M
Net Profit Margin (2022) XYZ 30.0% (2022 vs 2021)
* As of and is in US$
View Agenus Inc financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Agenus Inc premium industry data and analytics

110+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Agenus Inc’s relevant decision makers and contact details.

80+

Clinical Trials

Determine Agenus Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

80+

Catalyst Calendar

Proactively evaluate Agenus Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

60+

Pipeline Drugs

Identify which of Agenus Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

10+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

5

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

1

Marketed Drugs

Understand Agenus Inc’s commercialized product portfolio to stay one step ahead of the market.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Agenus Inc’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products Brands
Vaccines Pipeline: Stimulon
PhosphoSynVax for Cancers Prophage
AutoSynVax for Cancers Retrocyte Display
XYZ XYZ
XYZ XYZ
XYZ XYZ
Understand Agenus Inc portfolio and identify potential areas for collaboration Understand Agenus Inc portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2023 Regulatory Approval In April, the company was granted Fast Track Designation from the US Food and Drug Administration (FDA) for Botensilimab and Balstilimab in Colorectal Cancer.
2022 Contracts/Agreements In December, the company and The University of Kansas Cancer Center entered into an agreement with Targovax ASA to run a clinical trial testing mutant RAS vaccine TG01 in combination with PD-1 CPI balstilimab in pancreatic cancer.
2022 Contracts/Agreements In October, the company and VBI Vaccines Inc. announced a collaboration to evaluate the combination of VBI-1901, VBI’s cancer vaccine immunotherapeutic, and balstilimab, Agenus’ monoclonal antibody targeting the programmed death receptor-1 protein.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters Agenus Inc AbbVie Inc Novartis AG Amgen Inc Boehringer Ingelheim International GmbH
Headquarters United States of America United States of America Switzerland United States of America Germany
City Lexington North Chicago Basel Thousand Oaks Ingelheim am Rhein
State/Province Massachusetts Illinois - California Rheinland-Pfalz
No. of Employees 389 50,000 76,057 26,700 53,000
Entity Type Public Public Public Public Private
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Garo H. Armen, Ph.D. Chairman; Chief Executive Officer Executive Board 1999 70
Craig Winter Chief Information Officer Senior Management 2021 -
Robin E. Abrams Chief Legal Officer Senior Management 2022 -
Stephanie Fagan Chief Communications Officer Senior Management 2023 -
Tracy Mazza Clemente Chief People Officer Senior Management 2022 -
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Agenus Inc key executives to enhance your sales strategy Gain insight into Agenus Inc key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward